<DOC>
	<DOCNO>NCT00420316</DOCNO>
	<brief_summary>To assess long-term efficacy safety subject third year prim 2 dos GSK Biologicals ' oral live attenuate HRV vaccine ( Rotarix ) primary vaccination study ( 102247 ) . The Rotarix vaccine administer primary vaccination study . There vaccine/intervention long-term efficacy study .</brief_summary>
	<brief_title>Long-term Efficacy Safety Subjects Approximately 3 Years After Priming With 2 Doses GSK Bio 's HRV Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female complete second year efficacy followup primary vaccination study Finland . Written inform consent obtain parent guardian subject .</criteria>
	<gender>All</gender>
	<minimum_age>32 Months</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Intussusception</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Finland</keyword>
</DOC>